Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Tokio Marine & Nichido Fire Insurance Co., Ltd. (Head Office: Tokyo, President: Shinichi Hirose, “Tokio Marine Nichido”) announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates regarding Eisai’s in-house discovered LENVIMA??(lenvatinib mesylate, the orally available kinase inhibitor, “lenvatinib”), and Halaven??(eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor).
Eisai Co., Ltd. (Headqurters: Tokyo, CEO: Haruo Naito, “Eisai”) and Meiji Seika Pharma Co., Ltd. (Headqurters: Tokyo, CEO: Daikichiro Kobayashi, “Meiji”) today announced the manufacturing and marketing approval in Japan for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s disease under treatment with a drug containing levodopa for Equfina??TABLETS (safinamide mesilate, “safinamide”), which was developed for use in the treatment of patients with Parkinson’s disease was obtained. In Japan, Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer’s disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada.
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation
Under New FDA-Initiated Program, Combination Treatment Is the First to Receive Simultaneous Review Decisions in the U.S., Australia and Canada
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai’s sixth selection.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it received the 33rd?“IIA Japan Chairman’s Award” of the Institute of Internal Auditors – Japan (Chairman: Kazuhiko Fushiya, “IIA Japan”).
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test – Cogstate Brief Battery (CBB) – developed by Cogstate Ltd. (Headquarters: Australia, “Cogstate”), in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measures to the endemic regions in Kenya in collaboration with Merck (Headquarters: Darmstadt, Germany).
On August 7, 2019, Eisai China Inc. was invited to participate in a CPC sub-branch co-construction campaign in Zhenping organized and arranged by the School of Pharmacy of China Pharmaceutical University.? Seventeen people, including Shiying Zhang, Party Secretary of School of Pharmacy, Yan Huang, Deputy Party Secretary and other relevant leaders from China Pharmaceutical University, Ningbang Wang, Deputy Director of Jiangning High-tech Park Administrative Committee, Wei Guo, Chief Physician and Director of the Geriatric Endocrinology Department of Shaanxi Provincial People’s Hospital, Wei Cui, Chief Physician and? Director of? Department of Geriatric Endocrinology of First Affiliated Hospital of Xi’an Jiaotong University, Xiaojing Zhang, Director of the General Practice Department and Emergency Treatment Department of Second Affiliated Hospital of Xi’an Jiaotong University, as well as Xiongwei Gu Party Branch Secretary and head of Internal Audit Department of Eisai China Inc., came to Zhenping.? The co-construction campaign at this time mainly included: the drug donation by Eisai China Inc., experts’ free clinic services, “rational drug use” lectures, hierarchical diagnosis and treatment, transfer treatment, academic exchanges, etc.
